Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 15/20 | 0.67 |
| ▸ | KDM6B | O15054 | 2/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 5/20 | 0.53 |
| ▸ | KDM5A | P29375 | 2/20 | 0.51 |
| ▸ | KDM4A | O75164 | 1/20 | 0.51 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30589263 | 1.00 | KDM5B (0.67) | KDM5BKDM6BKDM4CKDM5AKDM4A | |
| SCHEMBL17891715 | 0.92 | KDM5B (0.67) | KDM5BKDM6BKDM4CKDM5AKDM2B | |
| SCHEMBL17891759 | 0.91 | KDM5B (0.56) | KDM5BKDM6BKDM4CKDM5AKDM2B | |
| SCHEMBL17891699 | 0.91 | KDM5B (0.67) | KDM5BKDM6BKDM4CKDM5AKDM2B | |
| SCHEMBL17891710 | 0.90 | KDM6B (0.68) | KDM5BKDM6BKDM4CKDM5AKDM2B | |
| SCHEMBL17891733 | 0.88 | KDM5B (0.69) | KDM5BKDM4CKDM2B | |
| SCHEMBL17891725 | 0.87 | KDM5B (0.69) | KDM5BKDM6BKDM4CKDM5AKDM2B | |
| SCHEMBL17891743 | 0.85 | KDM5B (0.70) | KDM5BKDM6BKDM4CKDM5AKDM2B | |
| SCHEMBL30589242 | 0.85 | KDM5B (0.70) | KDM5BKDM6BKDM4CKDM5AKDM2B | |
| SCHEMBL17898918 | 0.85 | KDM5B (0.61) | KDM5BKDM6BKDM4CKDM5AKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436445-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2023-09-06 | — | — | EP | claimed |
| EP-3436445-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2019-02-06 | — | — | EP | claimed |
| WO-2017161033-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-21 | — | — | WO | claimed |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. | 2016-07-07 | — | — | US | claimed |
| EP-3436445-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3436445-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3436445-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2019-02-06 | — | — | EP | disclosed |
| US-10174003-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174003-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-9896436-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-9896436-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| WO-2017161033-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161033-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. | 2016-07-07 | — | — | US | disclosed |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174003-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM3B | KDM5B 11/4885KDM6B 8/4885KDM4C 14/4885 |
| US-20160194306-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM5B 11/4885KDM6B 8/4885KDM4C 14/4885 |
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM5B 11/4885KDM6B 8/4885KDM4C 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.